Analyst Ratings for Enliven Therapeutics (ELVN)
ELVN Rating Summary
ELVN Price Target Summary
- Highest: $80.00 (Guggenheim)
- Lowest: $45.00 (BTIG)
- Average: $64.50
* Over Last 12-Mos
Overall Rating:
BUY
Rating Trend:
Avg. $ Target:
$64.50 (+21.2%)
* Over Last 12-Mos
Rating Score: 10 / 10
Percentile Rank: 95%
Avg. $ Target:
$64.50 (+21.2%)
* Over Last 12-Mos
Rating Score: 10 / 10
Percentile Rank: 95%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 6/8/2026 | Stifel » Updated 7/1/2026 |
Dara Azar | New Coverage | Buy (N/A) |
80.00 (60.00) |
34.71 (53.20) |
53.27% | Details |
| 5/12/2026 | Guggenheim | Michael Schmidt | New Coverage | Buy (N/A) |
80.00 (N/A) |
40.75 (53.20) |
30.55% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
